FDA Grants Approval to Axi-Cel for Adults With LBCL Following First-Line Chemoimmunotherapy
April 1st 2022Based on results of the ZUMA-7 trial, the FDA approved axicabtagene ciloleucel for the treatment of certain patients with large B-cell lymphoma who received chemoimmunotherapy in the frontline setting.